Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia B
A Retrospective Study to Describe the Incidence of Moderate to Severe Allergic Reactions to Factor IX in Patients With Hemophilia B
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Listed as NCT00195221, this observational or N/A phase trial focuses on Allergic Reactions and Hemophilia B and remains completed. Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, it has been updated 7 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: PHASE4 → None
-
Jan 2017 — Apr 2018 [monthly]
Completed PHASE4
First recorded
Feb 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Wyeth is now a wholly owned subsidiary of Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Atlanta, United States, Boise, United States, Brussels, Belgium, Calgary, Canada, Cardiff, United Kingdom, Catania, Italy, Catanzaro, Italy, Dayton, United States, East Lansing, United States, Fort Worth, United States and 28 more location s